Companies Plead for New Pharma Supply Chain Model

☞ | View the full content of this post. Exclusively available to ASQ Members.

By David McCann

The long-entrenched system of drug-manufacturer rebates has not adapted to changes in health-plan designs and labor-market trends.

A vast majority of benefits managers at large companies are dissatisfied with the pharmaceutical supply-chain model, which they consider to be complex, inefficient, and opaque.

With steeply rising drug prices being the single biggest component of overall healthcare cost increases in recent years, that model has developed into a significant concern.

But pricing, per se, is not the singular

☞ | View the full content of this post. Exclusively available to ASQ Members.